Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer (TEAM)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00279448
First received: January 17, 2006
Last updated: December 22, 2011
Last verified: December 2011
  Purpose

To compare recurrence free survival between two treatment groups (5 years with exemestane vs 2.5 to 3 years tamoxifen followed by 2 to 2.5 years of exemestane for a total duration of 5 years)

This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted. Link to TEAM Trial [971-ONC-0028-081/A5991026] Study Results: http://clinicaltrials.gov/ct2/show/results/NCT00036270?term=971-ONC-0028-081&rank=1


Condition Intervention Phase
Breast Neoplasms
Drug: exemestane
Drug: tamoxifen
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Open-Label Study To Compare The Efficacy, Tolerance And Quality Of Life Of 5 Years Of Adjuvant Exemestane (Aromasin) Therapy With 2.5 To 3 Years Of Adjuvant Tamoxifen Therapy, Followed By 2 To 2.5 Years Of Exemestane For A Total Duration Of 5 Years To Treat HR+ Post-Menopausal Patients With Non-Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • To compare recurrence free survival between two treatment groups. [ Time Frame: 2.75 years and 5 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The quality of life of patients treated with exemestane to that of patients treated with tamoxifen [ Time Frame: Every 3 months during first year then every 6 months for 4 years ] [ Designated as safety issue: No ]
  • Overall survival between the 2 treatment groups [ Time Frame: Every 3 months during first year then every 6 months for 4 years ] [ Designated as safety issue: Yes ]
  • Incidence of a second breast cancer (contralateral) between the 2 treatment groups [ Time Frame: Every 3 months during first year then every 6 months for 4 years ] [ Designated as safety issue: Yes ]
  • General tolerance in the short- and long-term between the 2 treatment groups [ Time Frame: Every 3 months during first year then every 6 months dor 4 years ] [ Designated as safety issue: Yes ]

Enrollment: 9779
Study Start Date: January 2002
Study Completion Date: June 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: exemestane
On tablet of 25 mg per day during 5 years
Other Name: Aromasin
Active Comparator: B Drug: tamoxifen
Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
Other Name: Kessar

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HR+ post-menopausal patients with non-metastatic breast cancer

Exclusion Criteria:

  • Any of the following: HR-, non-menopausal patient, metastatic breast cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00279448

  Hide Study Locations
Locations
France
Pfizer Investigational Site
Marseille, Be1 01971, France, 13285
Pfizer Investigational Site
Compiegne, Be1 02256, France, 60200
Pfizer Investigational Site
Rennes, Be1 03677, France, 35033
Pfizer Investigational Site
Brest, Be1 04292, France, 29609
Pfizer Investigational Site
Aix en Provence, France, 13616
Pfizer Investigational Site
Amiens, France, 80000
Pfizer Investigational Site
Annecy Cedex, France, 74011
Pfizer Investigational Site
Avignon Cedex 2, France, 84082
Pfizer Investigational Site
Bayonne, France, 64100
Pfizer Investigational Site
Blois, France, 41000
Pfizer Investigational Site
Bordeaux, France, 33076
Pfizer Investigational Site
Bordeaux CEDEX, France, 33000
Pfizer Investigational Site
Brest, France, 29283
Pfizer Investigational Site
Cagne sur Mer, France, 06805
Pfizer Investigational Site
Chalon sur Saone, France, 71100
Pfizer Investigational Site
Chaumont, France, 52000
Pfizer Investigational Site
Croix, France, 59170
Pfizer Investigational Site
Dijon, France, 21000
Pfizer Investigational Site
Douai, France, 59500
Pfizer Investigational Site
Draguignan, France, 83007
Pfizer Investigational Site
Dunkerque, France, 59240
Pfizer Investigational Site
Evreux, France, 27000
Pfizer Investigational Site
Hyres, France, 83400
Pfizer Investigational Site
L'Union, France, 31240
Pfizer Investigational Site
Le Havre, France, 76600
Pfizer Investigational Site
Lille, France, 59000
Pfizer Investigational Site
Lorient, France
Pfizer Investigational Site
Lyon, France, 69008
Pfizer Investigational Site
Mareuil les Meaux, France
Pfizer Investigational Site
Marseille, France, 13012
Pfizer Investigational Site
Marseille, France, 13009
Pfizer Investigational Site
Marseille, France, 13006
Pfizer Investigational Site
Metz, France, 57072
Pfizer Investigational Site
Montauban, France, 82017
Pfizer Investigational Site
Montbeliard, France, 25200
Pfizer Investigational Site
Montelimar, France, 26026
Pfizer Investigational Site
Montpellier, France, 34059
Pfizer Investigational Site
Mougins, France, 06250
Pfizer Investigational Site
Nancy, France, 54000
Pfizer Investigational Site
Nantes Cedex 2, France, 44202
Pfizer Investigational Site
Neuilly, France, 92200
Pfizer Investigational Site
NICE Cedex 1, France, 06050
Pfizer Investigational Site
Nimes, France, 30900
Pfizer Investigational Site
Paris, France, 75248
Pfizer Investigational Site
Pessac, France, 33600
Pfizer Investigational Site
Quincy sous Senart, France, 91480
Pfizer Investigational Site
Reims, France, 51100
Pfizer Investigational Site
Ris Orangis, France, 91130
Pfizer Investigational Site
Saint Brieuc, France, 22105
Pfizer Investigational Site
Saint Nazaire, France, 44600
Pfizer Investigational Site
St Cloud, France, 92210
Pfizer Investigational Site
St Herblain, France, 44805
Pfizer Investigational Site
Strasbourg, France, 67000
Pfizer Investigational Site
Toulon, France, 83056
Pfizer Investigational Site
Toulouse, France, 31400
Pfizer Investigational Site
Toulouse, France, 31000
Pfizer Investigational Site
Vandoeuvre les Nancy, France, 54511
Pfizer Investigational Site
Vannes, France, 56001
Pfizer Investigational Site
Vannes, France, 58000
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00279448     History of Changes
Other Study ID Numbers: EXEAPO-0028-118, A5991081
Study First Received: January 17, 2006
Last Updated: December 22, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Tamoxifen
Exemestane
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Selective Estrogen Receptor Modulators
Bone Density Conservation Agents
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014